EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Dupilumab in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in cystic fibrosis patients

Attilio Di Girolamo, Mattia Cristallo, Michelina Francesca Daddato, Federico Spataro, Giuseppina Leonetti, Pamela Vitullo, Eustachio Nettis

Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 678-681

DOI: 10.1016/j.jcf.2026.04.003 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Attilio Di Girolamo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area, Regional Reference Center for Allergic and Immunological Diseases, Bari, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cystic Fibrosis, Nasal Polyps, Rhinosinusitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic rhinosinusitis with nasal polyps (CRSwNP) manifests as either a solitary upper airway involvement or as part of a more intricate clinical picture, such as Cystic Fibrosis (CF). The altered viscoelastic properties of mucus facilitate the colonisation of bacteria, thereby instigating a process that perpetuates a state of chronic inflammation. Dupilumab, a monoclonal antibody that blocks IL-4/IL-13-signalling, has been demonstrated to improve nasal obstruction and the sense of smell. This observational real-life study comprised 10 patients diagnosed with CRSwNP and CF. The following scores were considered to ascertain the severity of rhinosinusitis: Nasal Polyp Score (NPS), Sino-Nasal Outcome Test (SNOT-22 score), Nasal Congestion/Obstruction Symptom severity score (NCS), Visual Analogue Scale for rhinosinusitis (VAS), and Loss of Smell score (LOS). Moreover, spirometry parameters and the number of new infections/hospital admissions were considered for lung involvement. Blood parameters, including the number of eosinophils and the total serum IgE level, were assessed. After six months of therapy, the median value of the NPS score decreased from 4 (IQR 1.75) to 1.5 (IQR 4.5; P < 0.01) and the SNOT-22 score from 55 (IQR 8.75) to 13.5 (IQR 13.5; P < 0.0001). FEV1 improved from a median value of 2.28 L (IQR 1.26) to 2.54 L (IQR 1.02). Serum IgE and blood eosinophil count did not change significantly. Dupilumab has proven to be effective in reducing the size of nasal polyps and improving associated symptoms in patients with CF who have type 2inflammation-related comorbidities, without the occurrence of adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCystic FibrosisNasal PolypsRhinosinusitisSinusitisAdultFemaleHumansMaleChronic DiseaseSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Cystic fibrosisDupilumabNasal polypsType 2 inflammation

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Precision and Regenerative Medicine and Ionian Area, Regional Reference Center for Allergic and Immunological Diseases, Bari, Italy.
  • Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, Post Graduate School of Allergy and Clinical Immunology, Guido Baccelli Unit of Internal Medicine, University of Bari Aldo Moro, 70124 Bari,…
  • Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro, 70124 Bari, Italy. Electronic address: federico.spataro@uniba.it.
  • Pediatric Cystic Fibrosis Centre, Azienda Universitaria Ospedaliera Consorziale Policlinico, Bari, Italy.
  • Cystic Fibrosis Support Center, Ospedale G. Tatarella di Cerignola, Cerignola, Italy.

Zitieren

APA

Di Girolamo, A., Cristallo, M., Daddato, M. F., Spataro, F., Leonetti, G., Vitullo, P., & Nettis, E. (2026). Dupilumab in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in cystic fibrosis patients. Journal of Cystic Fibrosis, 25(4), 678-681. https://doi.org/10.1016/j.jcf.2026.04.003

Vancouver

Di Girolamo A, Cristallo M, Daddato MF, Spataro F, Leonetti G, Vitullo P, et al. Dupilumab in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in cystic fibrosis patients. Journal of Cystic Fibrosis. 2026;25(4):678-681. doi:10.1016/j.jcf.2026.04.003

BibTeX
@article{DiGirolamo2026,
  author = {Di Girolamo, Attilio and Cristallo, Mattia and Daddato, Michelina Francesca and Spataro, Federico and Leonetti, Giuseppina and Vitullo, Pamela and Nettis, Eustachio},
  title = {Dupilumab in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in cystic fibrosis patients},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  volume = {25},
  number = {4},
  pages = {678--681},
  doi = {10.1016/j.jcf.2026.04.003}
}
Kostenlos starten →